Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:4/14/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the fourth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

    About MAESTRO-03
    ----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 67 clinical sites who will be administered either dirucotide or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 70% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Compan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical Announces 2008 Year End Results
2. BioMS Medical warrant extension
3. BioMS Medical to present at BIO CEO and Investor Conference
4. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
5. BioMS Medical recognized at Scrip Awards 2008
6. BioMS Medical Announces Third Quarter 2008 Results
7. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
11. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ELLYN, Ill. , July 2, 2015 ... Colton Eakins are gaining invaluable real-world experiences ... of Technology this summer. The students will ... Dr. Jeff Wereszczynski,s research group at IIT. The ... Dr. Tom Carter , Physics; Dr. Kathy ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, ... largest provider of surgical instruments to the Spine Industry. The acquisition of Turner ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The next-generation ... several key market segments, including the molecular diagnostics industry. BCC Research reveals in its ... of NGS-based tests, lower test costs, and a growing need for better diagnostics as ...
(Date:7/1/2015)... Ariz. , July 1, 2015 Isagenix ... it has earned three Gold, three Silver, and three ... Awards gala held in Chicago ... as the premier business awards program in the U.S. ... recognizes our company,s strength in developing leaders, cultivating talent, ...
Breaking Biology Technology:COD Students Participate in Prestigious Summer Internships 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
... ... EDMONTON, May 9 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS),a leading ... on its pipeline products, HYC750 and development with,BioCyDex Inc., The ... Inc. for HYC750, a technology based on hyaluronic acid that,has a ...
... Hungary, May 9 Genetic,Immunity, a US/Hungarian clinical-stage ... for targeted immune amplification, announced,today that the Company ... 5th,Annual Global Healthcare Conference to be held May ... in Monte Carlo, Monaco. The Company,s President,and Chief ...
... Celator Pharmaceuticals today,announced that Scott Jackson has been ... October 2007 as Head of Commercial,Development., "We ... CEO. He brings more than 20,years of pharmaceutical ... in oncology," said Dr. Joseph Mollica,Chairman of Celator,s ...
Cached Biology Technology:BioMS Medical Provides Update On Pipeline Products 2BioMS Medical Provides Update On Pipeline Products 3Genetic Immunity To Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO 2
(Date:6/16/2015)... GOTHENBURG, Sweden , June 16, 2015 ... including all touch fingerprint sensors in the company,s portfolio from ... . Deliveries are planned to mainly take place during the ... manufacturers in Asia . Jörgen ... another evidence of    the   growing interest from smartphone ...
(Date:6/15/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... announces that its leading payment security technology, the Wocket® smart ... NYC June 18th. Digital Experience! @ NYC is ... to over 300 of the top media covering the sector. ... New York City from 6:00 to ...
(Date:6/9/2015)... MINNETONKA, Minn. , June 9, 2015   ... that supports the entire spectrum of clinical research, will ... eClinical technology platform at the 2015 Drug Information ... on June 15-17.  These presentations will include ... be rolled out in the upcoming iMedNet ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... the idea has become predominant that the best way ... for it in the framework of markets. The great ... a glimpse of many possibilities for money-earning uses of ... Convention on Biological Diversity, a measure adopted in Rio ...
... colonies? To Kenya to count monkeys? To Tasmania to track ... in North America? No worries, theres a field guide ... and wacky but mostly practical field guides to ... purposeful knots and English churchyard lichens. Diane Schmidt, the ...
... than 99 percent of all modern potato varieties planted ... grew in the lowlands of south-central Chile. How Chilean ... from Europe-has been the subject of a long, contentious ... have maintained that Chilean potatoes were the first to ...
Cached Biology News:Markets of biodiversity and equity in trade: An illusion? 2Markets of biodiversity and equity in trade: An illusion? 3U. of I. librarian launches comprehensive Web database of field guides 2U. of I. librarian launches comprehensive Web database of field guides 3Using DNA, scientists hunt for the roots of the modern potato 2
...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... cell labeling mix, 92.5 MBq, ... stabilized with 0.1% 2-mercaptoethanol and ... acid. *Amino acid mixture for ... l-[35S]Methionine and l-[35S]Cysteine. * > ...
...
Biology Products: